Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival

Guy Pratt, Peter Thomas, Nicola Marden, Denis Alexander, Zadie Davis, David Hussey, Helen Parry, Stephen Harding, Daniel Catovsky, Joe Begley, David Oscier

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by heterogeneous clinical behavior and there is a need for improved biomarkers. The current study evaluated the prognostic significance of serum free light chains (sFLC, kappa, and lambda) and other serum markers (bar, serum thymidine kinase (sTK), soluble CD23, and LDH) together with established biomarkers in 289 patients enrolled into the LRF CLL4 trial. In a multivariable analysis of serum markers alone, higher big and kappa light chains were statistically significant in predicting disease progression and higher blg, and sTK in predicting mortality. In multivariable analysis for overall survival the following were independently significant: β2M levels, immunoglobulin gene (IGHV) mutational status (>98% homology), age, 17p13 deletions (>10%), and CD38 expression. β2M is the only serum marker that retained clear independent value as a biomarker in the LRF CLL4 trial and remains powerfully prognostic requiring evaluation in any future method of risk stratifying patients.

Original languageEnglish
Pages (from-to)2342-2350
Number of pages9
JournalLeukemia and Lymphoma
Volume57
Issue number10
DOIs
Publication statusPublished - 8 Feb 2016

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents/administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Biomarkers, Tumor
  • Female
  • Humans
  • Immunoglobulin Light Chains/blood
  • Leukemia, Lymphocytic, Chronic, B-Cell/blood
  • Male
  • Middle Aged
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Treatment Outcome
  • beta 2-Microglobulin/blood

Fingerprint

Dive into the research topics of 'Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival'. Together they form a unique fingerprint.

Cite this